253 related articles for article (PubMed ID: 26558272)
1. Targeting Cellular Metabolism Chemosensitizes the Doxorubicin-Resistant Human Breast Adenocarcinoma Cells.
Ma S; Jia R; Li D; Shen B
Biomed Res Int; 2015; 2015():453986. PubMed ID: 26558272
[TBL] [Abstract][Full Text] [Related]
2. Targeting P-glycoprotein function, p53 and energy metabolism: Combination of metformin and 2-deoxyglucose reverses the multidrug resistance of MCF-7/Dox cells to doxorubicin.
Xue C; Wang C; Sun Y; Meng Q; Liu Z; Huo X; Sun P; Sun H; Ma X; Ma X; Peng J; Liu K
Oncotarget; 2017 Jan; 8(5):8622-8632. PubMed ID: 28052008
[TBL] [Abstract][Full Text] [Related]
3. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
[TBL] [Abstract][Full Text] [Related]
4. ATP-dependent activity and mitochondrial localization of drug efflux pumps in doxorubicin-resistant breast cancer cells.
Dartier J; Lemaitre E; Chourpa I; Goupille C; Servais S; Chevalier S; Mahéo K; Dumas JF
Biochim Biophys Acta Gen Subj; 2017 May; 1861(5 Pt A):1075-1084. PubMed ID: 28214549
[TBL] [Abstract][Full Text] [Related]
5. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells.
Wang TX; Yang XH
Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331
[TBL] [Abstract][Full Text] [Related]
6. Effects of monensin liposomes on the cytotoxicity, apoptosis and expression of multidrug resistance genes in doxorubicin-resistant human breast tumour (MCF-7/dox) cell-line.
Shaik MS; Chatterjee A; Singh M
J Pharm Pharmacol; 2004 Jul; 56(7):899-907. PubMed ID: 15233869
[TBL] [Abstract][Full Text] [Related]
7. Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation.
Zhang ZL; Jiang QC; Wang SR
Breast Cancer; 2018 Mar; 25(2):233-242. PubMed ID: 29181822
[TBL] [Abstract][Full Text] [Related]
8. Reversion of multidrug resistance in a chemoresistant human breast cancer cell line by β-elemene.
Xu HB; Li L; Fu J; Mao XP; Xu LZ
Pharmacology; 2012; 89(5-6):303-12. PubMed ID: 22573000
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of c-fos by shRNA sensitizes adriamycin-resistant MCF-7/ADR cells to chemotherapeutic agents via P-glycoprotein inhibition and apoptosis augmentation.
Shi R; Peng H; Yuan X; Zhang X; Zhang Y; Fan D; Liu X; Xiong D
J Cell Biochem; 2013 Aug; 114(8):1890-900. PubMed ID: 23494858
[TBL] [Abstract][Full Text] [Related]
10. Effect of β-elemene on the kinetics of intracellular transport of d-luciferin potassium salt (ABC substrate) in doxorubicin-resistant breast cancer cells and the associated molecular mechanism.
Tang CY; Zhu LX; Yu JD; Chen Z; Gu MC; Mu CF; Liu Q; Xiong Y
Eur J Pharm Sci; 2018 Jul; 120():20-29. PubMed ID: 29704644
[TBL] [Abstract][Full Text] [Related]
11. Development of rational in vitro models for drug resistance in breast cancer and modulation of MDR by selected compounds.
Kars MD; Iseri OD; Gündüz U; Ural AU; Arpaci F; Molnár J
Anticancer Res; 2006; 26(6B):4559-68. PubMed ID: 17201178
[TBL] [Abstract][Full Text] [Related]
12. Reversing Multidrug Resistance in Chemo-resistant Human Lung Adenocarcinoma (A549/DOX) Cells by Algerian Propolis Through Direct Inhibiting the P-gp Efflux-pump, G0/G1 Cell Cycle Arrest and Apoptosis Induction.
Kebsa W; Lahouel M; Rouibah H; Zihlif M; Ahram M; Abu-Irmaileh B; Mustafa E; Al-Ameer HJ; Al Shhab M
Anticancer Agents Med Chem; 2018; 18(9):1330-1337. PubMed ID: 30088453
[TBL] [Abstract][Full Text] [Related]
13. Nelfinavir targets multiple drug resistance mechanisms to increase the efficacy of doxorubicin in MCF-7/Dox breast cancer cells.
Chakravarty G; Mathur A; Mallade P; Gerlach S; Willis J; Datta A; Srivastav S; Abdel-Mageed AB; Mondal D
Biochimie; 2016 May; 124():53-64. PubMed ID: 26844637
[TBL] [Abstract][Full Text] [Related]
14. Salinomycin enhances doxorubicin-induced cytotoxicity in multidrug resistant MCF-7/MDR human breast cancer cells via decreased efflux of doxorubicin.
Kim KY; Kim SH; Yu SN; Park SK; Choi HD; Yu HS; Ji JH; Seo YK; Ahn SC
Mol Med Rep; 2015 Aug; 12(2):1898-904. PubMed ID: 25892525
[TBL] [Abstract][Full Text] [Related]
15. Targeting P-glycoprotein expression and cancer cell energy metabolism: combination of metformin and 2-deoxyglucose reverses the multidrug resistance of K562/Dox cells to doxorubicin.
Xue C; Wang C; Liu Q; Meng Q; Sun H; Huo X; Ma X; Liu Z; Ma X; Peng J; Liu K
Tumour Biol; 2016 Jul; 37(7):8587-97. PubMed ID: 26733176
[TBL] [Abstract][Full Text] [Related]
16. A P-glycoprotein- and MRP1-independent doxorubicin-resistant variant of the MCF-7 breast cancer cell line with defects in caspase-6, -7, -8, -9 and -10 activation pathways.
Park SJ; Wu CH; Safa AR
Anticancer Res; 2004; 24(1):123-31. PubMed ID: 15015586
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia can impair doxorubicin resistance of non-small cell lung cancer cells by inhibiting MRP1 and P-gp expression and boosting the chemosensitizing effects of MRP1 and P-gp blockers.
Chen YL; Yang TY; Chen KC; Wu CL; Hsu SL; Hsueh CM
Cell Oncol (Dordr); 2016 Oct; 39(5):411-433. PubMed ID: 27306525
[TBL] [Abstract][Full Text] [Related]
18. A novel compound RY10-4 downregulates P-glycoprotein expression and reverses multidrug-resistant phenotype in human breast cancer MCF-7/ADR cells.
Xue P; Yang X; Liu Y; Xiong C; Ruan J
Biomed Pharmacother; 2014 Oct; 68(8):1049-56. PubMed ID: 25455158
[TBL] [Abstract][Full Text] [Related]
19. Gambogic acid sensitizes resistant breast cancer cells to doxorubicin through inhibiting P-glycoprotein and suppressing survivin expression.
Wang S; Wang L; Chen M; Wang Y
Chem Biol Interact; 2015 Jun; 235():76-84. PubMed ID: 25824409
[TBL] [Abstract][Full Text] [Related]
20. Coencapsulated doxorubicin and bromotetrandrine lipid nanoemulsions in reversing multidrug resistance in breast cancer in vitro and in vivo.
Cao X; Luo J; Gong T; Zhang ZR; Sun X; Fu Y
Mol Pharm; 2015 Jan; 12(1):274-86. PubMed ID: 25469833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]